Multiple additional CAR-T cell and TCR-T cell therapies are currently under preclinical and clinical investigation for various bone and soft tissue sarcomas, targeting antigens that include NY-ESO-1, GD2, interleukin-1 receptor accessory protein (IL1RAP), HER2, and B7-H3 [40,41,42,43]. Here, CD276 is linked to soft tissue sarcoma.